文献速递神经肌肉病神经免疫

泛神经束蛋白结旁病表现为暴发性吉兰-巴雷综合征的诊治要点

Pearls & Oy-Sters: Pan-Neurofascin Nodo-Paranodopathy Presenting as Fulminant Guillain-Barré Syndrome.
PubMed 文献 · Neurology · 2025-07-22

本文报告一例进行性无力患者初诊为吉兰-巴雷综合征,静脉注射免疫球蛋白后部分改善但数周后突然恶化,出现四肢瘫、下组颅神经受累及自主神经功能障碍,最终确诊为泛神经束蛋白抗体相关自身免疫性结旁病并启动利妥昔单抗后显著改善。文章讨论了该病的病理生理、临床及电生理特征、抗体检测与治疗考虑,并汇总迄今报道的40例病例特征。

要点

  • 泛神经束蛋白抗体相关结旁病可表现为暴发性吉兰-巴雷综合征样病程,需早期识别。
  • 提示早期检测泛神经束蛋白抗体的危险信号包括年龄大于60岁、严重快速进展的吉兰-巴雷综合征、延长机械通气、初步改善后暴发性复发及对标准治疗抵抗。
  • 利妥昔单抗抗体清除治疗是目前最佳治疗选择,早期使用可显著改变结局并可能挽救生命。

核心结论

  • 泛神经束蛋白抗体介导的自身免疫性结旁病是潜在危及生命的疾病,早期识别至关重要,因为早期抗体清除治疗可显著改变结局并可能挽救生命。

研究设计与样本

  • 本文为病例报告并复习文献,汇总迄今报道的40例泛神经束蛋白抗体相关自身免疫性结旁病病例的主要特征。

主要发现

  • 一例进行性无力患者初诊为吉兰-巴雷综合征,静脉注射免疫球蛋白后部分改善,但数周后突然恶化,出现四肢瘫、下组颅神经受累及自主神经功能障碍。
  • 该患者最终确诊为泛神经束蛋白抗体相关自身免疫性结旁病,启动利妥昔单抗后显著改善并维持缓解。
  • 泛神经束蛋白抗体相关自身免疫性结旁病通常呈单相病程,经适当治疗许多患者可实现完全或接近完全恢复。

关键数值与推荐

  • 提示早期检测泛神经束蛋白抗体的危险信号包括年龄大于60岁、严重且快速进展的吉兰-巴雷综合征、延长机械通气、初步改善后暴发性复发及对标准治疗抵抗。
  • 利妥昔单抗是目前最佳的抗体清除治疗选择。

临床怎么用

  • 对表现为严重、快速进展、对标准治疗抵抗或初步改善后暴发性复发的吉兰-巴雷综合征样患者,应警惕泛神经束蛋白抗体相关自身免疫性结旁病并早期检测抗体。
  • 确诊后应尽早启动利妥昔单抗等抗体清除治疗以改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autoimmune nodo-paranodopathy (AINP) associated with antibodies against pan-neurofascin (Ab-PanNF) is a rare subtype of autoimmune neuropathy. It can present as a severe, prolonged, and sometimes fatal disease. However, with appropriate treatment, it generally follows a monophasic course, and many patients achieve complete or near-complete recovery. Antibody-depleting therapy with rituximab (RTX) is currently the best therapeutic option. In this article, we report a patient with progressive weakness who was initially misdiagnosed with Guillain-Barré syndrome (GBS). Intravenous immunoglobulin (IVIg) led to partial improvement, but the patient deteriorated abruptly weeks later, developing tetraplegia, lower cranial nerve involvement, and dysautonomia. Eventually, a diagnosis of AINP with Ab-PanNF was reached, prompting the initiation of RTX. The patient improved dramatically and remains in remission. We discuss the pathophysiology underlying Ab-PanNF-mediated AINP, its clinical and electrodiagnostic features, and considerations regarding antibody testing and treatment. Specifically, red flags that should prompt early Ab-PanNF testing include age older than 60 years, severe and rapidly progressive GBS, prolonged mechanical ventilation, fulminant relapse after initial improvement, and resistance to standard treatments. Finally, we review the literature and summarize the main features of the 40 cases reported so far. Ab-PanNF-mediated AINP is a potentially life-threatening disease; its early recognition is of utmost importance because early antibody-depleting therapy significantly alters outcomes and can be lifesaving.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Cabral A, Lopes da Mota C, Rodrigues Casanova S, et al. Pearls & Oy-Sters: Pan-Neurofascin Nodo-Paranodopathy Presenting as Fulminant Guillain-Barré Syndrome. Neurology. 2025. PMID: 40694749. doi:10.1212/WNL.0000000000213848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。